Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference
Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference
PONTE VEDRA, Fla., Sept. 23, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to be a superior and safer chronic anticoagulant for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions, announced today it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2024 Investor Conference, taking place virtually on Tuesday, October 1, 2024.
佛罗里达州蓬特韦德拉，2024年9月23日 /PRNewswire/ — Cadrenal Therapeutics, Inc.（纳斯达克股票代码：CVKD）是一家处于后期阶段的生物制药公司，正在开发一种新的维生素K拮抗剂（VKA），旨在为植入心脏器械或罕见心血管疾病的华法林依赖患者提供更好、更安全的慢性抗凝剂。将在2024年10月1日星期二虚拟举行的Lytham Partners2024年秋季投资者会议上参加网络直播演讲，并主持与投资者的一对一会议。
Company Webcast
公司网络直播
Cadrenal's webcast presentation will begin at 2:00 pm ET on Tuesday, October 1. Access will be available via the conference home page at or directly at . The webcast will also be available for replay following the event.
Cadrenal的网络直播演示将于美国东部时间10月1日星期二下午2点开始。可通过会议主页或直接访问以下网址进行访问。活动结束后，网络直播也将可供重播。
One-on-one Meetings
一对一会议
Cadrenal management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting, please contact Lytham Partners at [email protected] or register for the event at .
在整个活动期间，肾上腺管理层将参加虚拟的一对一会议。如需安排会议，请通过 [email protected] 联系Lytham Partners或通过以下地址注册参加活动。
ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal Therapeutics is a late-stage biopharmaceutical company boldly challenging the status quo by innovating a new anticoagulant to elevate care for underserved patients. The company is developing the vitamin K antagonist (VKA) tecarfarin, designed to be a superior and safer anticoagulant for individuals with implanted cardiac devices or rare cardiovascular conditions. Cadrenal strives to improve outcomes and reduce major events for these patients, who lack chronic anticoagulation options besides warfarin, well-known for its prevalent side effects and cumbersome dosing. With its innovation, the company aims to unburden these patients and their healthcare providers from warfarin's many challenges.
关于肾上腺疗法公司
Cadrenal Therapeutics是一家处于后期阶段的生物制药公司，通过创新一种新的抗凝剂来提升对服务不足患者的护理，大胆地挑战现状。该公司正在开发维生素K拮抗剂（VKA）tecarfarin，该抗凝剂旨在为植入心脏器械或罕见心血管疾病的患者提供优质、更安全的抗凝剂。Cadrenal努力改善预后并减少这些患者的重大事件，这些患者除了华法林以其普遍的副作用和繁琐的剂量而闻名于世，还缺乏慢性抗凝选择。凭借其创新，该公司旨在减轻这些患者及其医疗保健提供者的负担，使其免受华法林的诸多挑战。
Cadrenal's late-stage drug candidate tecarfarin is a new VKA anticoagulant that is anticipated to result in fewer adverse events such as strokes, heart attacks, bleeds and deaths than warfarin. Tecarfarin received an orphan drug designation for heart failure patients with implanted left ventricular assist devices (LVADs) as well as both orphan drug and fast-track status for end-stage kidney disease patients with atrial fibrillation. Cadrenal is opportunistically pursuing pivotal trials along with clinical and commercial partnership opportunities. The company's plans also include studying tecarfarin in patients with mechanical heart valves experiencing anticoagulation difficulties. Visit .
Cadrenal的后期候选药物特卡法林是一种新的VKA抗凝剂，预计与华法林相比，它导致的中风、心脏病发作、出血和死亡等不良事件更少。Tecarfarin获得了针对植入左心室辅助装置（LVAD）的心力衰竭患者的孤儿药称号，同时为心房颤动的终末期肾脏疾病患者获得了孤儿药和快速通道资格。Cadrenal正在机会性地寻求关键试验以及临床和商业合作机会。该公司的计划还包括研究在出现抗凝困难的机械心瓣膜患者中使用替卡法林。访问。
For more information, please contact:
欲了解更多信息，请联系：
Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
[email protected]
肾上腺疗法：
首席财务官 Matthew Szot
858-337-0766
[电子邮件保护]
Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
[email protected]
投资者：
莱瑟姆合伙人有限责任公司
罗伯特·布鲁姆，管理合伙人
602-889-9700
[电子邮件保护]
SOURCE Cadrenal Therapeutics, Inc.
来源 Cadrenal Therapeutics, Inc.
